Denver News Updates

Metastatic Merkel Cell Carcinoma Pipeline Analysis Demonstrates Novel 13+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

 Breaking News
  • No posts were found

Metastatic Merkel Cell Carcinoma Pipeline Analysis Demonstrates Novel 13+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

March 15
10:34 2023
Metastatic Merkel Cell Carcinoma Pipeline Analysis Demonstrates Novel 13+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

DelveInsight’s, Metastatic Merkel Cell Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in the Metastatic Merkel Cell Carcinoma pipeline landscape. It covers the Metastatic Merkel Cell Carcinoma pipeline drug profiles, including Metastatic Merkel Cell Carcinoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Metastatic Merkel Cell Carcinoma Emerging drugs, the Metastatic Merkel Cell Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Metastatic Merkel Cell Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Metastatic Merkel Cell Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Metastatic Merkel Cell Carcinoma clinical trials studies, Metastatic Merkel Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Metastatic Merkel Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Metastatic Merkel Cell Carcinoma Pipeline Report

 

  • Over 13+ Metastatic Merkel Cell Carcinoma companies are evaluating 15+ Metastatic Merkel Cell Carcinoma pipeline therapies in various stages of development, and their anticipated acceptance in the Metastatic Merkel Cell Carcinoma market would significantly increase market revenue.

 

  • The leading Metastatic Merkel Cell Carcinoma Companies include Incyte Corporation, Transgene, Ocellaris Pharma, Roche, Exelixis, Sensei Biotherapeutics, Checkmate Pharmaceuticals, SOTIO Biotech, and others.

 

  • Promising Metastatic Merkel Cell Carcinoma Pipeline Therapies includes Retifanlimab, MLN0128, Pasireotide sub-cutaneous formulation, Nivolumab, Ipilimumab, Temsirolimus, Vinorelbine ditartrate, ⁸⁹Zr-Df-IAB22M2C Infusion, and others.

 

  • The Metastatic Merkel Cell Carcinoma companies and academics are working to assess challenges and seek opportunities that could influence R&D Metastatic Merkel Cell Carcinoma. The Metastatic Merkel Cell Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Metastatic Merkel Cell Carcinoma.

 

Request a sample and discover the recent breakthroughs happening in the Metastatic Merkel Cell Carcinoma Pipeline landscape @ Metastatic Merkel Cell Carcinoma Pipeline Outlook Report

 

Metastatic Merkel Cell Carcinoma Overview

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine tumor of the skin with increasing incidence. It most frequently presents on the head and neck region of elderly, white males. Specific risk factors include ultraviolet (UV) exposure, advancing age, and immunosuppression, and its development is associated with Merkel cell polyomavirus (MCPyV) infection. Skin biopsy is diagnostic, and sentinel lymph node evaluation should be performed in all patients who are diagnosed with MCC, as the disease typically has a rapidly progressive course. Treatment consists of wide local excision with or without adjuvant radiotherapy for the local disease. New therapies for metastatic MCC have shown promise and include immune-based therapies.

 

Metastatic Merkel Cell Carcinoma Emerging Drugs Profile

 

  • Retifanlimab: Incyte

 

Retifanlimab (formerly INCMGA0012), an investigational intravenous PD-1 inhibitor, is currently under evaluation in registration-directed trials as a monotherapy for patients with microsatellite instability-high endometrial cancer, Merkel cell carcinoma and squamous cell carcinoma of the anal canal (SCAC); and in combination with platinum-based chemotherapy for patients with non-small cell lung cancer and SCAC.

 

For further information, refer to the detailed Metastatic Merkel Cell Carcinoma Drugs Launch, Metastatic Merkel Cell Carcinoma Developmental Activities, and Metastatic Merkel Cell Carcinoma News, click here for Metastatic Merkel Cell Carcinoma Ongoing Clinical Trial Analysis

 

Metastatic Merkel Cell Carcinoma Pipeline Therapeutics Analysis

There are approx. 13+ key companies which are developing the therapies Metastatic Merkel Cell Carcinoma. The companies which have their Metastatic Merkel Cell Carcinoma drug candidates in the most advanced stage, i.e Phase II include Incyte

 

Metastatic Merkel Cell Carcinoma Pipeline Segmentation

Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous

 

Molecule Type

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Find out more about the Metastatic Merkel Cell Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Metastatic Merkel Cell Carcinoma Emerging Drugs @ Metastatic Merkel Cell Carcinoma Treatment Landscape

 

Scope of the Metastatic Merkel Cell Carcinoma Pipeline Report

 

  • Coverage- Global

 

  • Metastatic Merkel Cell Carcinoma Companies- Incyte Corporation, Transgene, Ocellaris Pharma, Roche, Exelixis, Sensei Biotherapeutics, Checkmate Pharmaceuticals, SOTIO Biotech, and others.

 

  • Metastatic Merkel Cell Carcinoma Pipeline Therapies- Retifanlimab, MLN0128, Pasireotide sub-cutaneous formulation, Nivolumab, Ipilimumab, Temsirolimus, Vinorelbine ditartrate, ⁸⁹Zr-Df-IAB22M2C Infusion, and others.

 

  • Metastatic Merkel Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

  

Dive deep into rich insights for drugs for Metastatic Merkel Cell Carcinoma Pipeline Companies and Therapies, click here @ Metastatic Merkel Cell Carcinoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Merkel Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Merkel Cell Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Retifanlimab: Incyte Corporation
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. SO-C101: SOTIO Biotech
  15. Drug profiles in the detailed report…..
  16. Preclinical Stage Products
  17. SNS 401 NG: Sensei Biotherapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Merkel Cell Carcinoma Key Companies
  21. Metastatic Merkel Cell Carcinoma Key Products
  22. Metastatic Merkel Cell Carcinoma- Unmet Needs
  23. Metastatic Merkel Cell Carcinoma- Market Drivers and Barriers
  24. Metastatic Merkel Cell Carcinoma- Future Perspectives and Conclusion
  25. Metastatic Merkel Cell Carcinoma Analyst Views
  26. Metastatic Merkel Cell Carcinoma Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Metastatic Merkel Cell Carcinoma Mergers and acquisitions, Metastatic Merkel Cell Carcinoma Licensing Activities @ Metastatic Merkel Cell Carcinoma Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories